10 million tonnes is under 2% of China's roughly 540 million tonnes of annual coal imports, so meeting it costs Beijing little, in sharp contrast to its agricultural and rare earth pledges, where the US administration has already flagged China as lagging behind. But this symbolic political win will be of minimal help to American coal. US coal exports to China collapsed 92% between 2024 and 2025 after Chinese retaliatory tariffs, and a combined duty still sitting near 30% on US coal keeps American cargoes structurally uncompetitive. Miners like Warrior Met Coal and Alpha Metallurgical Resources will see only a modest, politically directed volume bump, not a recovery of the market share lost. Indonesian, Australian, Russian and Mongolian miners, which now supply roughly 90% of China's overseas coal imports, stay comfortably unscathed.
The brand has produced only 4,700 of nearly 28,700 required locally-assembled compensation vehicles since its parent, Hozon New Energy, entered bankruptcy restructuring in China and stopped shipping parts, leaving its Bangchan assembly line stalled for over eight months. Thailand's Excise Department has already escalated from routine monitoring to formal compliance summons, and by mid-2027 its own extension deadlines and required bank guarantees run out, leaving no further room to delay a clawback that could reach 85% of each vehicle's value. Financially sound BYD and Great Wall Motors, who have long completed their production obligations in Thailand, stand to gain from sanctions on its lesser rivals.
India’s Power Ministry has ordered 112 captive coal plants to run at full capacity and sell surplus power from October to December as demand outstrips supply. The shortage is severe enough that Delhi is considering mandatory coal imports, which would disproportionately benefit Indonesian exporters that already supply roughly 80% of India’s imported coal. Adaro Energy (Indonesia’s largest coal producer) will secure the windfalls from surging Indian orders. As captive plants dump additional power to the market, domestic power companies will face pressure from dropping prices. Adani Power is left most exposed, with its plants already running at just 62.8% of capacity last quarter, and limited long-term contracts leave its margins vulnerable to price declines. Delhi’s attempt to ease its power shortage will deepen reliance on Indonesian coal while hurting Indian generators exposed to falling wholesale prices.
Yesterday Japan’s trade ministry announced ¥15 billion in subsidies for ENEOS, Idemitsu and Cosmo to complete refinery refits by year-end that will allow them to process more US energy and reduce reliance on Middle Eastern suppliers. As the largest investors in US shale and LNG, Mitsubishi and JERA are well placed to benefit from continued growth in US energy exports. Given the South Korea tariff deal with Trump contained very similar energy commitments, this story could also be read as tariff coercion producing parallel, independently negotiated outcomes in East Asia. Ironically, the geopolitical winners here would be India and China, who absorb the discounted Middle Eastern and Russian barrels that Japan/Korea are diversifying away from, strengthening Beijing's and New Delhi's leverage with Russia and the Gulf.
The Directorate of Revenue Intelligence (DRI) is investigating Samsung and LG paying only 5% instead of the full 15% tariff rate for imported OLED parts. Sony and Panasonic are next in line as both firms use the exact same OLED import-and-assembly structure that is now under DRI scrutiny. We’ve seen this before with the DRI in India's auto sector: a 2022 probe into Volkswagen widened to Kia, Mercedes-Benz and BMW. Chinese electronics maker TCL, which manufactures locally in India, stands to gain market share as its South Korean and Japanese rivals face growing customs scrutiny over the coming year.
PwC’s audit failures at Evergrande led Chinese regulators to impose major penalties and suspend the firm, turning auditor risk into a board-level concern for state-linked companies. The revised Audit Law regulation announced yesterday, and effective 1 December 2026, applies further pressure on foreign auditors by allowing the National Audit Office to refer suspected audit violations directly to China’s securities regulator (in essence formalising the enforcement route used against PwC over Evergrande). Because KPMG and EY absorbed the largest share of PwC’s former state-linked clients following the fiasco, they are now the foreign firms most exposed to this uneasy regulatory environment. And with banks such as Bank of Nanjing and Industrial Bank already moving away from the Big Four towards domestic firms, expect to see KPMG and EY partners checking over their shoulders.
India’s trade deal with the EU, due to be signed on 16 December, will give its pharmaceutical and technology exporters access to EU markets while keeping agriculture off the table. But, those protected sectors are precisely where US agriculture has been seeking greater access from a US–India trade deal. By giving Indian exporters another major market without agricultural concessions, the EU agreement reduces Washington’s leverage in its own trade negotiations with New Delhi. So, once the US midterms are over in November, the Trump administration is likely to turn to Russian-oil tariffs as its main pressure point. Reliance will be the likely target as India’s largest buyer of Rosneft crude — it accounts for more than 90% of India’s US-bound refined fuel exports.
Amidst rupiah depreciation volatility, Bank Indonesia has yet to expand currency protection tools to cover trade financing. This exposes businesses reliant on imports. KLBF, Southeast Asia’s largest pharmaceutical firm by market cap, will be hit hard because it imports roughly 90% of its active pharmaceutical ingredients (API). Chinese and Indian suppliers, which account for two thirds of KLBF’s API imports, will gain greater pricing power as a weaker rupiah pushes up KLBF’s import costs. KLBF typically holds three months of imported inventory, similar to the two-to-four-month buffer it maintained during the rupiah depreciation episodes of 2015 and 2018 — those reserves are about to be sorely tested.
China’s new licensing restrictions are set to tighten rare earths and graphite anode materials exports, both critical inputs for battery cells. Korean battery makers remain heavily reliant on Chinese graphite, leaving them exposed to higher costs and weaker short-term profits. POSCO Future M, South Korea’s only producer of non-Chinese graphite anodes stands to benefit as battery makers will shift away from China.
The Bank of Japan raised its policy rate to a 31-year high of 1.25%, citing AI-related investment as an inflation risk. Another rate increase to 1.5% expected by December. Record high rates are lifting lending margins at Mizuho, MUFG and SMFG. Japan’s push to attract AI investment is also raising financing costs for the foreign companies building that infrastructure, while shifting more of the gains from the investment boom towards domestic banks. SMFG looks to benefit the most with most of SMFG’s lending book concentrated in domestic loans — but Mizuho and MUFG also look to have a strong quarter, while TSMC and hyperscalers such as Microsoft, Amazon and Google building AI data centers in Japan face rising financing costs.
The Supreme Court’s September 22 criticism of excessive cancer-drug prices increases pressure on the National Pharmaceutical Pricing Authority to expand limits on the margins charged on patented cancer medicines. Roche’s Herceptin (trastuzumab) and Avastin (bevacizumab) are among the most likely early targets because both drugs have faced price disputes in India and already compete with established domestic generic alternatives, CANMAb and Abevmy from Biocon. As margin caps squeeze profits, foreign suppliers will struggle to match the production scale of domestic generic manufacturers. Better able to sustain high volumes at lower margins, domestic generics producers are therefore positioned to gain market share. Roche therefore faces the most immediate exposure, while AstraZeneca, Novartis and Bristol Myers Squibb face less risk because their leading patented cancer drugs do not yet have established Indian biosimilar competitors.
China–ASEAN trade is set to increase as the People’s Bank of China eases cross-border settlement and Hong Kong moves closer to joining the Regional Comprehensive Economic Partnership. So foreign banks (HSBC and SC) with established Southeast Asian networks will capture more MNC trade-finance business, squeezing domestic Chinese banks (who relied on the payment barriers to stay competitive). Beijing will accept the heat from domestic banks to bring more regional trade onto the renminbi payment system.